LAEKNA-B (02105) announced that the group has initiated patient enrollment for a Phase I multiple-dose expansion study of LAE102 targeting obesity treatment in China and has completed dosing the first participant.

This Phase I multiple-dose expansion study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE102 (subcutaneous injection) in 60 overweight/obese participants. Subjects will be randomly assigned to either the LAE102 group or the placebo group for a six-month treatment period.

Based on the positive one-month treatment results observed in the previous MAD study, this pre-planned multiple-dose expansion study aims to further assess the efficacy and safety profile after prolonged continuous treatment. The group is committed to providing this precision therapy for patients with obesity or metabolic disorders who require novel treatment options.